Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.22 - $9.31 $22,815 - $965,530
-103,709 Closed
0 $0
Q2 2024

Nov 14, 2024

SELL
$0.28 - $1.16 $180,631 - $748,329
-645,112 Reduced 86.15%
103,709 $34,000
Q2 2024

Aug 13, 2024

SELL
$0.28 - $1.16 $180,631 - $748,329
-645,112 Reduced 86.15%
103,709 $34,000
Q1 2024

Nov 14, 2024

SELL
$1.06 - $1.67 $1.08 Million - $1.71 Million
-1,022,615 Reduced 57.73%
748,821 $868,000
Q1 2024

May 13, 2024

BUY
$1.06 - $1.67 $793,750 - $1.25 Million
748,821 New
748,821 $868,000
Q4 2023

Nov 14, 2024

BUY
$1.26 - $1.79 $2.1 Million - $2.99 Million
1,667,727 Added 1608.08%
1,771,436 $2.99 Million
Q4 2023

Feb 09, 2024

SELL
$1.26 - $1.79 $451,595 - $641,552
-358,409 Reduced 16.83%
1,771,436 $2.99 Million
Q3 2023

Nov 14, 2023

BUY
$1.61 - $2.54 $13,651 - $21,536
8,479 Added 0.4%
2,129,845 $3.86 Million
Q2 2023

Aug 11, 2023

SELL
$1.14 - $1.95 $177,485 - $303,593
-155,689 Reduced 6.84%
2,121,366 $3.95 Million
Q1 2023

May 12, 2023

SELL
$1.2 - $2.19 $53,272 - $97,222
-44,394 Reduced 1.91%
2,277,055 $3.03 Million
Q4 2022

Feb 13, 2023

BUY
$1.63 - $3.52 $919,365 - $1.99 Million
564,028 Added 32.09%
2,321,449 $3.92 Million
Q3 2022

Nov 15, 2022

BUY
$0.73 - $3.74 $34,772 - $178,147
47,633 Added 2.79%
1,757,421 $5.48 Million
Q2 2022

Aug 15, 2022

SELL
$2.2 - $4.2 $720,715 - $1.38 Million
-327,598 Reduced 16.08%
1,709,788 $4.07 Million
Q1 2022

May 13, 2022

BUY
$2.83 - $8.69 $286,622 - $880,123
101,280 Added 5.23%
2,037,386 $8.21 Million
Q4 2021

Feb 11, 2022

SELL
$8.31 - $14.92 $5.67 Million - $10.2 Million
-681,720 Reduced 26.04%
1,936,106 $16.1 Million
Q3 2021

Nov 12, 2021

BUY
$9.15 - $13.28 $24 Million - $34.8 Million
2,617,826 New
2,617,826 $30.3 Million

Others Institutions Holding DNA

About Ginkgo Bioworks Holdings, Inc.


  • Ticker DNA
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 1,287,779,968
  • Market Cap $9.25B
  • Description
  • Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agric...
More about DNA
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.